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Br J Pharmacol. 2019;1–11.Background and purpose: PDE inhibitors such as sildenafil alleviate lower urinary
tract symptoms; however, a complete understanding of their action on the bladder
remains unclear. We are investigating the effects of sildenafil, on post and pregangli-
onic nerve‐mediated contractions of the mouse bladder, and neuronal and urothelial
ATP release.
Experimental approach: Bladders were used from young (12 weeks), aged
(24 months), and spinal cord transected (SCT), mice, for in vitro contractility experi-
ments. An arterially perfused in situ whole mouse model was used to record bladder
pressure. Nerve‐mediated contractions were generated by electrical field stimulation
(EFS) of postganglionic nerve terminals or the pelvic nerve. ATP release during EFS in
intact detrusor strips, and during stretch of isolated mucosa strips, was measured
using a luciferin‐luciferase assay.
Key results: Sildenafil (20 μM) inhibited nerve‐mediated contractions in young
mice, with an increase in f 1/2 values in force–frequency relationships, demonstrating
a greater effect at low frequencies. Sildenafil reduced the atropine‐resistant,
purinergic component of nerve‐mediated contractions, and suppressed neuronal
ATP release upon EFS in vitro. Sildenafil reduced the preganglionic pelvic nerve
stimulated bladder pressure recordings in situ; comparable to in vitro experiments.
Sildenafil reduced stretch‐induced urothelial ATP release. Sildenafil also relaxed
nerve‐mediated contractions in aged and SCT mice.
Conclusion and implications: Sildenafil has a greater effect on the low‐frequency,
purinergic‐mediated contractions and suppresses neuronal ATP release. In addition,
sildenafil reduces stretch‐induced urothelial ATP release. These results demonstrate- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
e Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any
d and is not used for commercial purposes.
ogy published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
; EFS, electrical field stimulation; IDO, idiopathic bladder overactivity; LUT, lower urinary tract; LUTS, lower urinary tract symptoms;
dder; SCT, spinal cord transection; TTX, tetrodotoxin.
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2 CHAKRABARTY ET AL.BJPa novel action of sildenafil to selectively inhibit ATP release from nerve terminals
innervating detrusor smooth muscle and the urothelium.What is already known
• Sildenafil alleviates lower urinary tract symptoms;
however, its action on the bladder is unclear.
What this study adds
• Sildenafil reduces purinergic‐mediated contractions and
selectively and completely inhibits neuronal and
urothelial ATP release.
What is the clinical significance
• Sildenafil may target pathological pathways associated
with enhanced purinergic motor and sensory pathways.1 | INTRODUCTION
Lower urinary tract symptoms (LUTS) associated with bladder pathol-
ogies, such as overactive bladder (OAB) and neurogenic bladder dys-
function, and also with ageing are highly prevalent and can have a
severe effect on the quality of life of patients. Current treatments
for LUTS have recognized limitations, including uncertain efficacy
and adverse effects. PDE5 inhibitors such as sildenafil (Viagra®),
which are used to treat erectile dysfunction (Hatzimouratidis et al.,
2010), also alleviate LUTS (McVary et al., 2007). The entire lower uri-
nary tract (LUT) expresses PDE5 (Fibbi et al., 2010; Filippi et al., 2007),
and studies support the use of PDE5 inhibitors to reduce LUTS, utiliz-
ing the NO/cGMP pathway on several potential targets. These include
increasing LUT oxygenation, decreasing afferent nerve activity, nega-
tively regulating proliferation of LUT stroma and LUTS‐related inflam-
mation (Gacci et al., 2016). The ability of sildenafil to relax smooth
muscle directly has also been demonstrated, where sildenafil‐induced
relaxation of human detrusor strips is significantly decreased using a
soluble GC inhibitor to block the formation of cGMP (Oger et al.,
2010). However, a complete understanding of their actions on the
peripheral control of bladder contractile function remains unclear. In
this study, the effects of sildenafil on nerve‐mediated contractions
of isolated mouse detrusor strips, as well as on in situ bladder function,
were characterized in young adult, aged, and spinal cord injured mice.
In particular, the action of sildenafil on ATP‐mediated processes was
investigated. ATP is co‐released along with ACh in parasympathetic
endings to detrusor. With human detrusor, ATP is a functional trans-
mitter only in overactive pathologies (Bayliss, Wu, Newgreen, Mundy,
& Fry, 1999) and so regulation of its release would be a therapeutic
target. Moreover, stretch‐activated ATP release from the urothelium,
proposed to finally activate bladder afferents, is also enhanced in
OAB pathologies (Cheng et al., 2014), thus providing a possible cause
for urinary urgency. The effect on neuronal and urothelial neurotrans-
mitter release was also investigated. A comprehensive description of
how sildenafil reduces contractile function will give insight into the
pathology of bladder functional disorders and should suggest potential
therapeutic mechanisms of PDE5 inhibitors in their treatment.2 | METHODS
2.1 | Tissue samples and ethics approval
All animal care and experimental procedures were in compliance with
the University of Bristol Ethics Committee and in accordance with UK
legislation under the Animals (Scientific Procedures) Act 1986 Amend-
ment Regulations (SI 2012/3039). Animal studies are reported in com-
pliance with the ARRIVE guidelines (Kilkenny et al., 2010) and with therecommendations made by the British Journal of Pharmacology. Young
(12 weeks) and aged (24 months) male C57BL/6 mice (Harlan UK Ltd)
were used for experiments.2.2 | Spinal cord transection
Twelve‐week old male mice underwent complete spinal cord transec-
tion (SCT) at theT8–T9 level as previously described (Ikeda et al., 2012;
Kadekawa et al., 2017; McCarthy et al., 2009). In brief, a laminectomy
was performed at the T8–T9 spinal level under sterile surgical condi-
tions. The spinal cord was transected and the cavity cleared to ensure
complete transection, the space between cut ends was filled with a
haemostatic sponge, and muscle layers and overlying skin were closed
with sutures. The surgery was performed under ketamine (70 mg·kg−1,
i.p.) and medetomidine (0.5 mg·kg−1, i.p.) and upon recovery the
mice were injected with atipamezole (1.0 mg·kg−1, i.p.) and
buprenorphine (0.03 mg·kg−1, s.c.). Mice were also treated with ampi-
cillin (0.10 mg·kg−1, s.c.) twice daily for 5 days post‐SCT to prevent
urinary tract infections. Bladders of SCT mice were emptied by
gentle abdominal compression and perineal stimulation twice a day
for 5 days post‐SCT. SCT mice were then killed with pentobarbital
sodium (20–40 mg per mouse) and used for experiments.2.3 | Measurement of contractile function in vitro
Young (normal and SCT) and aged mice were killed by cervical disloca-
tion, and the bladder was removed through a midline laparotomy. The
whole bladder was bisected and bladder strips from the bladder dome
(detrusor with mucosa intact, 4‐ to 5‐mm length, 1‐ to 2‐mm width)
were tied to a hook and an isometric force transducer in a horizontal
trough. Preparations were superfused with Tyrode's solution at 37°C.
Contractures were generated by exposure to carbachol (CCh, 1 μM)
CHAKRABARTY ET AL. 3BJPor high‐K+ (80 mM) Tyrode's. Contractions generated by electrical
field stimulation (EFS; 0.1‐ms pulses, 1–40 Hz, 3‐s train every 90 s)
that were inhibited by tetrodotoxin (TTX, 1 μM). With some prepara-
tions, TTX‐resistant contractions were present, generated by direct
muscle stimulation, and were insensitive to atropine and α,β‐
methylene ATP (ABMA). Sildenafil (20 μM, see Section 3) was added
to the superfusate and the effect on agonist‐ and nerve‐mediated con-
tractions measured. These were subtracted from the EFS contraction,
leaving a nerve‐mediated contraction. Tension amplitude (mN) was
normalized to preparation weight (mN·mg−1). Nerve‐mediated ampli-
tude, T(f), plotted as a function of stimulation frequency, f , was fitted
to Equation (1a). The frequency‐dependent percentage reduction
of force, R(f), by an intervention was fitted to Equation (1b).
For frequency‐dependent ATP release, ATP(f), data were fitted to
Equation (1c).
T fð Þ ¼ Tmaxf
n
fn1=2 þ fn
(1a)
R fð Þ ¼ RLf − RLf − RHfð Þ:f
mÞ
fm þ kmð Þ
 
þ RHf
 
(1b)
ATP ¼ ATPb þ ATPmaxf
n
fn1=2 þ fn
 !
; (1c)
where Tmax is maximum tension at high frequencies, f 1/2 is the fre-
quency to attain Tmax/2, and n is a constant (Pakzad et al., 2016): RLf
and RHf are the maximum and minimum force reductions respectively
at low and high frequencies, m and k are constants. ATPb is a
frequency‐independent component of ATP release from detrusor
preparations. Data fits were performed with an iterative, least‐squares
algorithm (KaleidaGraph, v4.5, Synergy software, CA, USA). Drug
interventions were delivered via the superfusate, with appropriate
vehicle and time controls.
2.4 | Measurement of nerve‐mediated ATP release
in 12‐week normal and SCT mice
Superfusate samples (100 μl) were taken from a fixed point near the
preparation, (two‐thirds downstream along the tissue length and 1‐
mm lateral to the horizontally mounted preparation), and with minimal
mechanical disturbance. Samples were taken before EFS, and 2 s after
the initiation of EFS, the nerve‐mediated release was taken as the dif-
ference in these two values. Samples were stored on ice before assay
of released ATP using a luciferin‐luciferase assay where the emitted
light was proportional to the concentrations of ATP. The complete
Sigma ATP assay mix (FLAAM, Sigma‐Aldrich, Dorset, UK) was diluted
with the assay buffer supplied as per the manufacturer's instructions.
Luminescence intensity was read using a luminometer (Glomax
20/20, Promega) and calibrated with an ATP standard on the day of
each experiment, with luminescence as a linear function of concentra-
tion on a log–log plot over the range of 100 fM to 1 μM. Neuronal
ATP release was inhibited by the application of 1‐μM TTX.Appropriate controls were carried out in background solutions using
the solvents and chemicals tested. The detection limit of the system
was 100‐fM ATP.2.5 | Measurement of mucosa ATP release in
12‐week‐old normal mice
The mucosa was separated from underlying detrusor by blunt dissec-
tion, mounted in a similar way to detrusor preparations to an isometric
force transducer in the horizontal trough and superfused withTyrode's
solution, with or without sildenafil (20 μM). The hook was connected
to a voltage‐activated solenoid that allowed rapid extension (within
1 s) of the tissue by 20% of the original length for 50 s before resto-
ration (within 1 s) to the original length. Samples were taken and
assayed, as above, before extension and at various time points upon
extension, before and after drug interventions.2.6 | Measurement of nerve‐mediated contractile
function in situ
Young mice were administered heparin (50 IU, i.p.) and anaesthetized
with isoflurane (2%) until loss of paw withdrawal reflex, following the
non‐recovery procedure modified from previous studies with an in situ
arterially perfused rat (Sadananda, Drake, Paton, & Pickering, 2011)
and mouse (Ito et al., 2019; Ito, Drake, Fry, Kanai, & Pickering,
2018). The brain was removed, and the spinal cord pithed with a blunt
wire before arterial perfusion of the preparation. Both ureters were
ligated to prevent natural bladder filling, the urethra was clamped,
and a catheter was inserted into the bladder lumen to record
intravesical pressure and maintain isovolumetric conditions. A glass
suction electrode (tip diameter ~100 μm) was used to stimulate the
left pelvic nerve once it had been dissected clear of underlying tissue.
Nerve‐mediated bladder contractions were generated using an iso-
lated stimulator (Digitimer Ltd. UK; 0.1‐ms pulses, 1–24 Hz, 3‐s train
every 90 s) and the pressure amplitude (mmHg) was analysed. Female
mice were used due to difficulties in successfully dissecting and stim-
ulating the pelvic nerve in male mice. Nerve‐mediated whole bladder
pressure amplitude, P, as a function of frequency, f , was fitted to
Equation (1a), with peak pressure, P, values substituting for tension,
T, values. Drug interventions were delivered arterially.2.7 | Data and statistical analysis
Data are mean ± SEM and differences between data sets were tested
with repeated measures two‐way ANOVA followed by parametric
post hoc tests; the null hypothesis was rejected at P < 0.05. n values
refer to the number of preparations, one each from separate animals.
The data and statistical analysis comply with the recommendations of
the British Journal of Pharmacology on experimental design and analysis
in pharmacology (Curtis et al., 2018). All statistical analyses were
undertaken using GraphPad® Prism 7 (GraphPad Software Inc., CA,
USA; GraphPad Prism, RRID:SCR_002798). The number of repeats in
4 CHAKRABARTY ET AL.BJPeach control and intervention set was based on a power calculation to
reject the null hypothesis at P < 0.05 and a power of 80%, with vari-
ance of data based on previous experience data with these methods.
2.8 | Materials
Tyrode's solution was composed of (mM): NaCl, 118; NaHCO3, 24;
KCl, 4.0; NaH2PO4, 0.4; MgCl2, 1.0; CaCl2, 1.8; glucose, 6.1; Na pyru-
vate, 5.0; 5% CO2, 95% O2, pH 7.4.
The concentration of all stock solutions was between 1.0 and
10 mM. Sildenafil was dissolved in DMSO. CCh, atropine, and ABMA
were dissolved in distilled water. Stock solutions were diluted with
Tyrode's solution to the final concentration as indicated. All chemicals
were from Sigma‐Aldrich (Dorset, UK), except ABMA from Merck
Millipore (Watford, UK).
2.9 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY (Harding et al., 2018), and are permanently archived in
the Concise Guide to PHARMACOLOGY 2017/18 (Alexander,
Christopoulos, et al., 2017, Alexander, Fabbro, et al., 2017, Alexander,
Peters, et al., 2017).FIGURE 1 The effect of sildenafil (1–100 μM) on (a) carbachol (CCh,
1 μM, n = 8) and (b) high‐K+ (80 mM, n = 5) induced contractions in
isolated detrusor from 12‐week‐old mice. Data are mean ± SEM.
*P < 0.05. Data are fitted to Equation (1b), Section 23 | RESULTS
3.1 | Agonist‐induced contractions in isolated
detrusor: Effect of sildenafil
The peak force of the CCh (1 μM) contracture was significantly
reduced by sildenafil at concentrations 1–100 μM. An IC50 value
was determined for each preparation, with a mean IC50 value of
5.4 ± 2.2 μM and a residual force of 49.5 ± 4.7% (n = 8: Figure 1a). Sil-
denafil also reduced high‐K+ contracture, with a mean IC50 value of
16.0 ± 9.6 μM and a residual force of 42.3 ± 13.6% (n = 8: Figure 1
b). The vehicle control, DMSO, had no effect on CCh and high‐K+ con-
tractures, except at concentrations used for 30‐ to 100‐μM test solu-
tions when force was reduced by 9.6 ± 2.1%. A test dose of 20‐μM
sildenafil was used for subsequent experiments with nerve‐mediated
contractions.
3.2 | Nerve‐mediated contractions in isolated
detrusor: Effect of sildenafil
A combination of ABMA (10 μM, to desensitize ionotropic purinergic
receptors) and atropine (1 μM, to block muscarinic receptors)
abolished nerve‐mediated contractions in detrusor from 12‐week
mice. Thus, nerve‐mediated contractions are mediated by ACh and
ATP release. Force–frequency relationships (Figure 2a) show atropine
alone reduced contractions more at high frequencies, and ABMAalone had a greater effect at low frequencies, data are shown for
12‐week mice. This was quantified by calculation of f 1/2 values (see
Figure 2a control curve) that were reduced by atropine and increased
by ABMA (Figure 2b). Thus, ATP as a neurotransmitter is released
more at low stimulation frequencies and ACh at higher frequencies.
With detrusor from 24‐month mice, atropine and ABMA had similar
effects on f 1/2 as in detrusor from young mice (Figure 2bii). In addi-
tion, control Tmax and f 1/2 values were not significantly different with
young and aged mice (young vs. aged: Tmax, control; 1.77 ± 0.35 vs.
0.97 ± 0.37 mN·mm−2; n = 8.5).
Sildenafil (20 μM) reduced nerve‐mediated contractions in isolated
detrusor preparations from 12‐week (Figure 2c) and 24‐month mice.
Figure 2d plots the percentage reduction of force by sildenafil at each
frequency in 12‐week and 24‐month mice, with a greater reduction of
force at lower stimulation frequencies compared to that at higher
FIGURE 2 (a) Frequency‐response curves
for nerve‐mediated contractions in control
(n = 8) and in the presence of α,β‐methylene
ATP (ABMA, 1 μM, n = 6) or atropine (1 μM,
n = 6). Data are plotted as a percentage of the
maximum estimated contraction under control
conditions, Tmax,control. The value of the f1/2
for the control curve is shown, that is, the
frequency to achieve Tmax/2. The fits are from
Equation (1a), Section 2. (b) f1/2 values for
control conditions (n = 8), and in the presence
of ABMA (n = 6) and atropine (n = 6), the value
in the presence of 20‐μM sildenafil is also
shown (n = 8, 5). *P < 0.05; data are for 12‐
week‐old mice (bi) and 24‐month‐old mice
(bii). (c) Traces of nerve‐mediated contractions
under control conditions and with 20‐μM
sildenafil. The frequency values are those
used to elicit nerve‐mediated responses. (d)
Percentage reduction of nerve‐mediated
contractions by sildenafil with preparations
from 12‐week‐old (left, n = 8) and 24‐month‐
old (right, n = 5) mice. Fits are from
Equation (1b), Section 2. All group data are
mean ± SEM
CHAKRABARTY ET AL. 5BJPfrequencies. This was corroborated by an increase of f 1/2 value in
both the 12‐week and 24‐month mice data (Figure 2bi and 2bii),
where values were increased to those similar to that in ABMA.
The difference between the contraction suppression by sildenafil at
high and low frequencies (ΔRLf − RHf, Equation 1b) is a measure of
the purinergic component of the contraction if it blocks ATP release
during nerve stimulation (see Figure 3a below). With detrusor from
24‐month mice, this was significantly greater than with 12‐week
mice (64.9 ± 7.6 vs. 41.3 ± 7.6%, P = 0.05, n = 5.8 respectively), sug-
gesting a more significant contribution from purinergic transmission
in 24‐month mice. Thus, the action of sildenafil may be due either
to a reduction of ATP release during nerve stimulation or a selective
inhibition of the action of ATP on detrusor. However, the latter
is unlikely as sildenafil also attenuated contractures mediated by
CCh (Figure 1a). Accordingly, the first hypothesis was tested byinvestigating the mode of action of sildenafil with detrusor from
12‐week mice.3.3 | Nerve‐mediated and stretch‐induced ATP
release: Effect of sildenafil
Nerve‐mediated ATP release was measured directly by measuring
superfusate [ATP] near the preparation. In control conditions,
a frequency‐dependent release of [ATP] was superimposed on a
background fraction (ATPb, Figure 3a); data were analysed between
1 and 16 Hz. With subsequent addition of 20‐μM sildenafil, ATPb
was not significantly different (0.54 vs. 0.43 pmol·μl−1, n = 7);
however, the frequency‐dependent component was completely
abolished.
FIGURE 3 (a) Frequency‐dependent nerve‐mediated ATP release from 12‐week‐old mice under control conditions (n = 6) and in the presence of
20‐μM sildenafil (n = 6). Data were fitted to Equation (1b), Section 2. (b) Stretch‐activated ATP from the mucosa of from 12‐week‐old mice under
control conditions (n = 6) and in the presence of 20‐μM sildenafil (n = 6). Samples were obtained 2 min prior, during, and 0.5, 1.0, 2.0, 5.0, and
10.0 min after a 50‐s stretch. All group data are mean ± SEM. *P < 0.05
6 CHAKRABARTY ET AL.BJPPrevious studies have shown that the mucosa is also a source of
ATP, especially when stretched and it was of interest to determine if
this also is affected by sildenafil. Rapid stretch by 20% of the resting
length for 50 s was followed by restoration of the original length.
Superfusate samples were collected prior to stretch, during the
stretch, and at 0.5, 1.0, 2.0, 5.0, and 10.0 min after restoration. In con-
trol conditions, ATP release peaked at 2 min after restoration to nearly
60‐fold increased over pre‐stretch levels and remained elevated after
10 min. Sildenafil (20 μM) did not affect pre‐stretch levels but signifi-
cantly attenuated the post‐stretch increase (Figure 3b).
3.4 | Bladder contractions evoked by preganglionic
pelvic nerve stimulation: Effect of sildenafil
The preganglionic pelvic nerve was dissected as much as possible from
adhering tissue and stimulated in situ in 12‐week mice (Figure 4a) to
generate intravesical bladder pressure transients (Figure 4b). The fre-
quency dependence was identical to in vitro contractions through
postganglionic nerve stimulation (Figure 4c). Sildenafil (20 μM) also
reduced the amplitude of the pressure transients with an action
greater at lower frequencies (Figure 4d), as also observed in vitro,
Figure 2d. Thus, as above, the f 1/2 value was increased by sildenafil
(3.7 ± 0.4 vs. 6.0 ± 0.6 Hz, respectively, n = 5, P < 0.05).
3.5 | Nerve‐mediated contractions and ATP release
in spinal cord‐transected mice: Effect of sildenafil
Sildenafil (20 μM) reduced nerve‐mediated contractions in SCT 12‐
week mice, with a greater effect at low stimulation frequencies as
observed in young and aged mice with an intact spinal cord (Figure 5
a). The inset shows that f 1/2 values were significantly increased with
sildenafil. Nerve‐mediated ATP release was also measured that was
also abolished by sildenafil and superimposed on a background release
(ATPb, Figure 5b). When compared with 12‐week intact mice, the
frequency‐dependent release of ATP was however significantly
smaller: for example, at 8 Hz stimulation, the frequency‐dependentATP release was 2.63 ± 0.62 versus 0.54 ± 0.12 pmol·g−1 (n = 8.5;
P < 0.05) in normal and SCT 12‐week mice.4 | DISCUSSION
4.1 | Actions of sildenafil on detrusor and efferent
nerve activity
PDE5 inhibitors, such as sildenafil and tadalafil, are successfully used
to manage erectile dysfunction, and it has also been observed that
they relieve LUTS, especially in men with benign prostatic hyperplasia,
although there is no consensus about their principal modes of action
(Andersson, 2018; Gacci et al., 2016). This study, using mice, con-
firmed a direct relaxant effect of sildenafil on detrusor smooth muscle,
with a similar potency to that with human detrusor (Oger et al., 2010)
where it was proposed to act by altering cyclic nucleotide levels
and modulating K+ channel activity, such as KATP and BK channels.
However, there has been less investigation of their action on nerve‐
mediated contractions, and this study reports a substantial and
frequency‐dependent action. It cannot be excluded that the concen-
tration chosen for interventions (i.e., 20 μM) had an effect on other
PDEs; however, this concentration was that which produced a half‐
maximal relaxation in in vitro experiments.
Parasympathetic postganglionic fibres activate detrusor by release
of ACh and ATP and abolition of contractions by atropine and ABMA
implies that muscarinic and P2X1 receptors mediate this process, in
contrast to the situation in guinea pig detrusor (Kennedy, Tasker,
Gallacher, & Westfall, 2007). In most animals and human OAB, both
transmitters are functionally active, although in normal human blad-
ders, only ACh has a role due to high ectoATPase activity (Bayliss
et al., 1999; Harvey, Skennerton, Newgreen, & Fry, 2002). Sildenafil
suppressed nerve‐mediated contractions but more at low stimulation
frequencies (i.e., 1–4 Hz) so it is unlikely this was due only to a direct
effect on smooth muscle. Release of noradrenaline and ATP in the
sympathetic nervous system can be separately regulated (Speirs,
FIGURE 4 (a) Schematic diagram of the
arterially perfused in situ mouse model used
for preganglionic pelvic nerve stimulation
(n = 6). The pelvic nerve was dissected and
stimulated. (b) Traces of nerve‐mediated
whole bladder pressure contractions during
control conditions and in the presence of
20‐μM sildenafil. (c) Force– and pressure–
frequency relationships with data from the
same 12‐week‐old mice obtained in situ
(P/Pmax) and in vitro (T/Tmax). Data fitted to
Equation (1a), Section 2. (d) Percentage
reduction of nerve‐mediated pressure
transients by sildenafil with preparations from
12‐week‐old mice (n = 6), data fitted to
Equation (1b), Section 2. All group data are
mean ± SEM
CHAKRABARTY ET AL. 7BJPDonnelly, Lynch, Scholfield, & Johnson, 2006). Differential release of
ACh and ATP in detrusor parasympathetic endings also occurs (Pakzad
et al., 2016), where ATP release is reduced selectively by A1 receptor
agonists. The cellular pathways regulating separate release of ATP andACh remain to be established; however, it has potential implications
for therapeutic management of human OAB, as ATP is a functional
transmitter in this condition. The ability of sildenafil to regulate
ATP release selectively was more directly shown by its abolition of
FIGURE 5 (a) Nerve‐mediated contractions from spinal cord
transected (SCT) 12‐week‐old mice under control conditions and in
the presence of 20‐μM sildenafil (n = 5). Data were fitted to
Equation (1a), Section 2. The inset shows the respective f1/2 values,
*P < 0.05. (b) Frequency‐dependent nerve‐mediated ATP release in
12‐week‐old SCT mice under control conditions (n = 5) and in the
presence of 20‐μM sildenafil (n = 5). Data were fitted to Equation (1c),
Section 2. All data are mean ± SEM
8 CHAKRABARTY ET AL.BJPTTX‐sensitive, frequency‐dependent release of ATP. EFS may possibly
result in urothelial ATP release in these experimental conditions,
either by direct stimulation (Sadananda, Shang, Liu, Mansfield, &
Burcher, 2009) or indirectly by the changes in muscle contraction.
However, sildenafil reduced both neuronal and urothelial ATP release
in this study.
In vitro experiments with isolated detrusor preparations were
mirrored by stimulation of preganglionic fibres in an in situ model.
The frequency dependence of pressure transients mirrored that of
contractions in vitro and were similarly influenced by sildenafil. This
implies that the actions of sildenafil may be explained only by its
action at the postganglionic junction and on smooth muscle, with
no separate action on preganglionic fibres. The data also imply that
under these experimental conditions, the pelvic ganglion does not
modulate the gain of pre to postganglionic transmission.4.2 | Sildenafil effects on mucosal ATP release and
afferent signalling
The mucosa exerts considerable effects on detrusor contractile perfor-
mance; it reduces contractility (Hawthorn, Chapple, Cock, & Chess‐
Williams, 2000) but enhances spontaneous activity (Ikeda & Kanai,
2008). Mucosal influence over spontaneous activity is in part due to
stretch‐mediated ATP release (Kushida & Fry, 2016), and the observa-
tion that sildenafil greatly reduced such ATP release offers another
route for the PDE5 inhibitor to reduce detrusor contractile function.
Of note, A1 receptor agonists and sildenafil both reduce stretch‐
activated mucosal ATP release (Dunning‐Davies, Fry, Mansour, &
Ferguson, 2013), as well as nerve‐mediated release, suggesting a com-
mon regulator of ATP release in these two tissues. Another proposed
role for mucosal ATP release is suburothelial afferent nerve activation
to provide a transduction pathway between bladder wall stretch and
sensation (Vlaskovska et al., 2001). Sildenafil reduces bladder afferent
activity (Behr‐Roussel et al., 2011), but it has to be determined if the
action is a direct one on nerves or indirectly through modulation of
mucosal ATP release.4.3 | Sildenafil and the ageing bladder
Ageing is associated with fibrosis and either a decline or maintenance
of detrusor contractile function in animal and human models
(Fry, Bayliss, Young, & Hussain, 2011; Kamei et al., 2018; Lluel et al.,
2000). More consistent is the increased significance of purinergic
neurotransmission with age (Yoshida, Miyamae, Iwashita, Otani, &
Inadome, 2004), greater purinergic receptor expression (Daly et al.,
2014), and enhanced stretch‐mediated mucosal ATP release (Sui
et al., 2014). This suggests a potential role for sildenafil to suppress
neural and mucosal release of ATP that is associated with OAB in
humans. Data here (Figure 2d) showed the frequency‐dependent
reduction of nerve‐mediated contractions by sildenafil was greater in
aged animals, suggesting an increased purinergic component in neuro-
muscular transmission.4.4 | Sildenafil and bladder function with spinal cord
injury
A greater role for purinergic transmission and mucosal release is also
suggested in idiopathic and neurogenic bladder overactivity (IDO,
NDO). Atropine resistance, suggesting functional purinergic transmis-
sion, is a feature of IDO and NDO (Bayliss et al., 1999) but the data
here showed nerve‐mediated ATP release was actually smaller in
SCT mice. If this is extrapolated to the human condition, purinergic
contractions can only be explained by reduced hydrolysis of ATP in
the neuromuscular junction, as indeed observed in detrusor from
patients with IDO and NDO (Fry et al., 2018). Mucosal ATP release
is also reported in tissue isolated from OAB (Khera, Somogyi, Kiss,
Boone, & Smith, 2004; Salas, Somogyi, Gangitano, Boone, & Smith,
2007; Smith et al., 2008) which will potentially increase afferent
CHAKRABARTY ET AL. 9BJPfiring for a given stretch of the bladder wall. Both targets are there-
fore useful for PDE5 inhibitors to suppress, potentially to alleviate
symptoms of OAB. This approach offers an advantage over current
therapeutic pathways to suppress OAB that use muscarinic receptor
antagonists, receptors that mediate the normal mode of bladder
contraction.4.5 | Conclusions
The PDE5 inhibitor sildenafil exerts a direct detrusor relaxant
effect as previously reported. The novel finding of this study is that
sildenafil also selectively and completely inhibits ATP release
from motor nerves to detrusor, as well as stretch‐activated release
from the mucosa. The particular pathways whereby this effect is
mediated is yet to be determined—for example, is this a NO/cGMP
dependent effect. This blockade was observed not just in young
animal animals but also in aged animals and those subjected to spinal
cord injury. The significance of this observation in aged and SCT
animals is that in humans, these conditions are especially
associated with OAB syndromes and enhanced purinergic motor
and sensory pathways. This offers the possibility that PDE5
inhibitors will be useful to suppress OAB symptoms by suppressing
pathological pathways in humans, rather than suppressing normal
physiological pathways, as occurs at present with current therapeutic
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